Abstract
Allograft loss remains a severe clinical problem after kidney transplantation. The molecular mechanism of graft loss is a complex process involving T and/or B cell activation, inflammation responses, autophagy and apoptosis. Since these pathways are involved in immune responses in kidney transplant rejection, application of genetic interference to inhibit specific pathways could present an effective targeted gene therapy method. Recent studies have successfully attempted to use gene therapy to target the key molecules involved in immune responses during transplantation. This strategy has the potential to silence target genes associated with a variety of diseases, including those that trigger allograft loss following organ transplantation. In this review, we have discussed evidence of the clinical applicability of gene therapy in kidney transplantation based on known associations between kidney diseases and genes participating in the underlying mechanisms. The molecules contributing to immune responses and inflammatory injury are further highlighted as potential targets in future clinical therapy for renal transplantation.
Keywords: Gene therapy, Kidney transplantation, RNAi, siRNA, ESRD, Inferior vena cava.
Current Gene Therapy
Title:Gene Therapy in Kidney Transplantation: Evidence of Efficacy and Future Directions
Volume: 17 Issue: 6
Author(s): Jiawei Li, Guisheng Qi, Guowei Tu, Cheng Yang*Ruiming Rong*
Affiliation:
- Department of Urology, Zhongshan Hospital, Fudan University, Shanghai,China
- Department of Urology, Zhongshan Hospital, Fudan University, Shanghai,China
Keywords: Gene therapy, Kidney transplantation, RNAi, siRNA, ESRD, Inferior vena cava.
Abstract: Allograft loss remains a severe clinical problem after kidney transplantation. The molecular mechanism of graft loss is a complex process involving T and/or B cell activation, inflammation responses, autophagy and apoptosis. Since these pathways are involved in immune responses in kidney transplant rejection, application of genetic interference to inhibit specific pathways could present an effective targeted gene therapy method. Recent studies have successfully attempted to use gene therapy to target the key molecules involved in immune responses during transplantation. This strategy has the potential to silence target genes associated with a variety of diseases, including those that trigger allograft loss following organ transplantation. In this review, we have discussed evidence of the clinical applicability of gene therapy in kidney transplantation based on known associations between kidney diseases and genes participating in the underlying mechanisms. The molecules contributing to immune responses and inflammatory injury are further highlighted as potential targets in future clinical therapy for renal transplantation.
Export Options
About this article
Cite this article as:
Li Jiawei , Qi Guisheng , Tu Guowei , Yang Cheng *, Rong Ruiming *, Gene Therapy in Kidney Transplantation: Evidence of Efficacy and Future Directions, Current Gene Therapy 2017; 17 (6) . https://dx.doi.org/10.2174/1566523218666180214095606
DOI https://dx.doi.org/10.2174/1566523218666180214095606 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nitric Oxide as a Marker for Levo-Thyroxine Therapy in Subclinical Hypothyroid Patients
Current Vascular Pharmacology Evidence for Pleiotropic Effects of Statins in Clinical Trials
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) A Review of the Chemical and Pharmacological Aspects of the Genus Marrubium
Current Pharmaceutical Design Assessment of Phytochemicals and Herbal Formula for the Treatment of Depression through Metabolomics
Current Pharmaceutical Design Novel Therapeutic Targets for Prevention and Therapy of Sepsis Associated Acute Kidney Injury
Current Drug Targets Pharmacological Effects of RAAS Blockade in Ischemic Nephropathy
Current Drug Metabolism Experimental and Clinical Application of Plasmid DNA in the Field of Central Nervous Diseases
Current Gene Therapy Nitric Oxide Synthase Function in Exercise
Current Enzyme Inhibition The Autocrine/Paracrine Loop After Myocardial Stretch: Mineralocorticoid Receptor Activation
Current Cardiology Reviews Common Pathways in Health Benefit Properties of RSV in Cardiovascular Diseases, Cancers and Degenerative Pathologies
Current Pharmaceutical Biotechnology The Challenges of Blood Pressure Control in Dialysis Patients
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Editorial (Thematic Issue: Renal Endothelial Dysfunction: Evolving Concepts And Perspectives)
Cardiovascular & Hematological Disorders-Drug Targets Stress, Cardiovascular Diseases and Surgery-Induced Angiogenesis
Current Angiogenesis (Discontinued) Targeting Notch Pathway in Cancer Diagnostics and Therapeutics: An Emerging Approach
Recent Patents on Anti-Cancer Drug Discovery Chemistry and Biological Activities of Buxus Alkaloids
Current Bioactive Compounds Vascular Disease and Insulin-Like Growth Factor-1
Vascular Disease Prevention (Discontinued) Inflammatory Mechanisms and Oxidative Stress as Key Factors Responsible for Progression of Neurodegeneration: Role of Brain Innate Immune System
CNS & Neurological Disorders - Drug Targets Testosterone and Cardioprotection Against Myocardial Ischemia
Cardiovascular & Hematological Disorders-Drug Targets Histone Deacetylase (HDAC) Inhibitors - emerging roles in neuronal memory, learning, synaptic plasticity and neural regeneration
Current Neuropharmacology Ghrelin as a Neuroprotective and Palliative Agent in Alzheimer's and Parkinson's Disease
Current Pharmaceutical Design